Femke Noorman
Research Subjects
Femke Noorman has a total of 191 co-authors. Here are the top co-authors by number of shared publications:
- Tim W. H. Rijnhout
Department of Surgery Alrijne Medical Center Leiderdorp The Netherlands
6 shared publications - Rigo Hoencamp
Department of Surgery, Alrijne Medical Centre, 2353 GA Leiderdorp, the Netherlands; Trauma Research Unit Department of Surgery, Erasmus MC, University Medical Centre Rotterdam, 3000 CA Rotterdam, the Netherlands; Defence Healthcare Organization, Ministry of Defence, 3584 AB Utrecht, the Netherlands; Department of Surgery, Leiden University Medical Centre, 2333 ZA Leiden, the Netherlands
5 shared publications - Lacey Johnson
Research and Development Australian Red Cross Lifeblood Alexandria New South Wales Australia
4 shared publications - Michael H. J. Verhofstad
Trauma Research Unit Department of Surgery, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
4 shared publications - Oscar J. F. van Waes
Trauma Research Unit, Department of Surgery, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
4 shared publications - Boke Linso Sjirk Borger van der Burg
Department of Surgery, Alrijne Hospital, Leiderdorp, The Netherlands
3 shared publications
Latest Publications
- 18 May 2026
- Published by Wiley in Transfusion
- Vol. 66 (8) , 1536-1551
Barriers and facilitators to cell saver use in damage control surgery
Background: Cell savers reduce the use of allogeneic blood and can serve as an important adjunct during blood shortages. This study investigates the user perspective on cell saver (CS) use during damage control surgery (DCS) in the Netherlands. Study Design and Methods: A survey was conducted amongst trauma surgeons and anesthesiologists from Dutch level 1 trauma centers and military‐affiliated hospitals. The survey assessed the perceived usability and usefulness of CS in DCS, addressing factors such as logistics, training, experience, (contra)indications, and perceived suitability of CS or reinfusion of unwashed salvaged blood during blood shortages. Responses were analyzed using a five‐point scale. Results: 195 of the 707 (28%) invited clinicians completed the survey. Most rated CS as very useful or essential during DCS (trauma surgeons: 58%, anesthesiologists: 64%). Staff (90%) and disposables (84%) were reportedly available, but reported concerns included CS being time‐consuming (trauma: 23%, anesthesia: 40%), contamination risk from gastrointestinal injuries (trauma: 37%, anesthesia: 21%), and insufficient suction power (trauma: 19%, anesthesia: 10%). During blood shortages, most respondents considered CS suitable for DCS (trauma: 54%, anesthesia: 63%), but fewer supported reinfusion of unwashed salvaged blood (trauma: 62%, anesthesia: 25%). Discussion: The routine use of CS during DCS may be hampered by practical and clinical barriers, such as time constraints, limited training, and the risk of complications. Targeting these areas and correlating these findings to clinical outcomes may increase the use of autologous blood transfusion techniques.
- 18 May 2026
- Published by Wiley in Transfusion
- Vol. 66 (8) , 1536-1551
Barriers and facilitators to cell saver use in damage control surgery
Background: Cell savers reduce the use of allogeneic blood and can serve as an important adjunct during blood shortages. This study investigates the user perspective on cell saver (CS) use during damage control surgery (DCS) in the Netherlands. Study Design and Methods: A survey was conducted amongst trauma surgeons and anesthesiologists from Dutch level 1 trauma centers and military‐affiliated hospitals. The survey assessed the perceived usability and usefulness of CS in DCS, addressing factors such as logistics, training, experience, (contra)indications, and perceived suitability of CS or reinfusion of unwashed salvaged blood during blood shortages. Responses were analyzed using a five‐point scale. Results: 195 of the 707 (28%) invited clinicians completed the survey. Most rated CS as very useful or essential during DCS (trauma surgeons: 58%, anesthesiologists: 64%). Staff (90%) and disposables (84%) were reportedly available, but reported concerns included CS being time‐consuming (trauma: 23%, anesthesia: 40%), contamination risk from gastrointestinal injuries (trauma: 37%, anesthesia: 21%), and insufficient suction power (trauma: 19%, anesthesia: 10%). During blood shortages, most respondents considered CS suitable for DCS (trauma: 54%, anesthesia: 63%), but fewer supported reinfusion of unwashed salvaged blood (trauma: 62%, anesthesia: 25%). Discussion: The routine use of CS during DCS may be hampered by practical and clinical barriers, such as time constraints, limited training, and the risk of complications. Targeting these areas and correlating these findings to clinical outcomes may increase the use of autologous blood transfusion techniques.
- Open Access
- 10 April 2025
- Published by Wiley in Transfusion
- Vol. 65 (5) , 950-955
Massive transfusion policy in the Netherlands, a nationwide survey
Background: Massive transfusion protocols (MTPs) guide the physician in optimizing transfusion strategies. Although international guidelines on massive transfusion exist, it is unknown whether all Dutch hospitals adhere to these guidelines. The main objective of this study was to create an overview of the massive transfusion strategies of Dutch hospitals and to evaluate if logistical factors, for example, the unavailability of thawed plasma, influence transfusion practices. Furthermore, this study was initiated to evaluate the interest in a ready‐to‐use plasma product.Study Design and Methods: A questionnaire on transfusion strategy, available resources, and yearly usage/wastage of transfusion products was distributed to all hospitals in the Netherlands.Results: Sixty‐nine hospitals were approached, of which 58 responded (response rate 84%). The majority of hospitals (67%) strived for a 1:1 erythrocyte/plasma ratio. Five percent of the hospitals used an erythrocyte/plasma ratio >2:1, which did not meet (inter)national guidelines. No relation was found between the clinical strategy described in the MTP and available resources; moreover, direct plasma availability did not increase plasma wastage. Hospitals for which it takes longer to have plasma available for transfusion generally are more interested in a ready‐to‐use plasma product (n = 55, 75.0% vs. 57%).Conclusion: This was the first nationwide survey on massive transfusion practices in the Netherlands. There is clear uniformity when it comes to using an MTP. Logistics surrounding plasma availability or plasma thawing capacity did not influence MTPs. Nevertheless, there seems to be substantial interest in a ready‐to‐use plasma product, especially in hospitals with limited plasma use.
- 10 April 2025
- Published by Wiley in Transfusion
- Vol. 65 (5) , 950-955
Open AccessMassive transfusion policy in the Netherlands, a nationwide survey
Background: Massive transfusion protocols (MTPs) guide the physician in optimizing transfusion strategies. Although international guidelines on massive transfusion exist, it is unknown whether all Dutch hospitals adhere to these guidelines. The main objective of this study was to create an overview of the massive transfusion strategies of Dutch hospitals and to evaluate if logistical factors, for example, the unavailability of thawed plasma, influence transfusion practices. Furthermore, this study was initiated to evaluate the interest in a ready‐to‐use plasma product.Study Design and Methods: A questionnaire on transfusion strategy, available resources, and yearly usage/wastage of transfusion products was distributed to all hospitals in the Netherlands.Results: Sixty‐nine hospitals were approached, of which 58 responded (response rate 84%). The majority of hospitals (67%) strived for a 1:1 erythrocyte/plasma ratio. Five percent of the hospitals used an erythrocyte/plasma ratio >2:1, which did not meet (inter)national guidelines. No relation was found between the clinical strategy described in the MTP and available resources; moreover, direct plasma availability did not increase plasma wastage. Hospitals for which it takes longer to have plasma available for transfusion generally are more interested in a ready‐to‐use plasma product (n = 55, 75.0% vs. 57%).Conclusion: This was the first nationwide survey on massive transfusion practices in the Netherlands. There is clear uniformity when it comes to using an MTP. Logistics surrounding plasma availability or plasma thawing capacity did not influence MTPs. Nevertheless, there seems to be substantial interest in a ready‐to‐use plasma product, especially in hospitals with limited plasma use.
- 1 December 2022
- Published by Wiley in Transfusion
- Vol. 63 (1) , 217-228
Assessment of the soluble proteins HMGB1, CD40L and CD62P during various platelet preparation processes and the storage of platelet concentrates: The BEST collaborative study
Background: Structural and biochemical changes in stored platelets are influenced by collection and processing methods. This international study investigates the effects of platelet (PLT) processing and storage conditions on HMGB1, sCD40L, and sCD62P protein levels in platelet concentrate supernatants (PCs).Study Design/Methods: PC supernatants (n = 3748) were collected by each international centre using identical centrifugation methods (n = 9) and tested centrally using the ELISA/Luminex platform. Apheresis versus the buffy coat (BC‐PC) method, plasma storage versus PAS and RT storage versus cold (4°C) were investigated. We focused on PC preparation collecting samples during early (RT: day 1–3; cold: day 1–5) and late (RT: day 4–7; cold: day 7–10) storage time points.Results: HMGB1, sCD40L, and sCD62P concentrations were similar during early storage periods, regardless of storage solution (BC‐PC plasma and BC‐PC PAS‐E) or temperature. During storage and without PAS, sCD40L and CD62P in BC‐PC supernatants increased significantly (+33% and +41%, respectively) depending on storage temperature (22 vs. 4°C). However, without PAS‐E, levels decreased significantly (−31% and −20%, respectively), depending on storage temperature (22 vs. 4°C). Contrastingly, the processing method appeared to have greater impact on HMGB1 release versus storage duration. These data highlight increases in these parameters during storage and differences between preparation methods and storage temperatures.Conclusions: The HMGB1 release mechanism/intracellular pathways appear to differ from sCD62P and sCD40L. The extent to which these differences affect patient outcomes, particularly post‐transfusion platelet increment and adverse events, warrants further investigation in clinical trials with various therapeutic indications.
- 1 December 2022
- Published by Wiley in Transfusion
- Vol. 63 (1) , 217-228
Assessment of the soluble proteins HMGB1, CD40L and CD62P during various platelet preparation processes and the storage of platelet concentrates: The BEST collaborative study
Background: Structural and biochemical changes in stored platelets are influenced by collection and processing methods. This international study investigates the effects of platelet (PLT) processing and storage conditions on HMGB1, sCD40L, and sCD62P protein levels in platelet concentrate supernatants (PCs).Study Design/Methods: PC supernatants (n = 3748) were collected by each international centre using identical centrifugation methods (n = 9) and tested centrally using the ELISA/Luminex platform. Apheresis versus the buffy coat (BC‐PC) method, plasma storage versus PAS and RT storage versus cold (4°C) were investigated. We focused on PC preparation collecting samples during early (RT: day 1–3; cold: day 1–5) and late (RT: day 4–7; cold: day 7–10) storage time points.Results: HMGB1, sCD40L, and sCD62P concentrations were similar during early storage periods, regardless of storage solution (BC‐PC plasma and BC‐PC PAS‐E) or temperature. During storage and without PAS, sCD40L and CD62P in BC‐PC supernatants increased significantly (+33% and +41%, respectively) depending on storage temperature (22 vs. 4°C). However, without PAS‐E, levels decreased significantly (−31% and −20%, respectively), depending on storage temperature (22 vs. 4°C). Contrastingly, the processing method appeared to have greater impact on HMGB1 release versus storage duration. These data highlight increases in these parameters during storage and differences between preparation methods and storage temperatures.Conclusions: The HMGB1 release mechanism/intracellular pathways appear to differ from sCD62P and sCD40L. The extent to which these differences affect patient outcomes, particularly post‐transfusion platelet increment and adverse events, warrants further investigation in clinical trials with various therapeutic indications.
- Open Access
- 1 November 2022
- Published by Wiley in Transfusion
- Vol. 63 (1) , 203-216
Frozen for combat: Quality of deep‐frozen thrombocytes, produced and used by The Netherlands Armed Forces 2001–2021
Background: The Netherlands Armed Forces (NLAF) are using −80°C deep‐frozen thrombocyte concentrate (DTC) since 2001. The aim of this study is to investigate the effect of storage duration and alterations in production/measurement techniques on DTC quality. It is expected that DTC quality is unaffected by storage duration and in compliance with the European guidelines for fresh and cryopreserved platelets.Study Design and Methods: Pre‐freeze and post‐thaw product platelet content and recovery were collected to analyze the effects of dimethyl sulfoxide (DMSO) type, duration of frozen storage (DMSO‐1 max 12 years and DMSO‐2 frozen DTC max 4 years at −80°C) and type of plasma used to suspend DTC. Coagulation characteristics of thawed DTC, plasma and supernatant of DTC (2× 2500 G) were measured with Kaolin thromboelastography (TEG) and phospholipid (PPL) activity assay.Results: Platelet content and recovery of DTC is ±10%–15% lower in short‐stored products and remained stable when stored beyond 0.5 years. Thawed DTC (n = 1724) were compliant to the European guidelines (98.1% post‐thaw product recovery ≥50% from original product, 98.3% ≥200 × 109 platelets/unit). Compared to DMSO‐1, products frozen with DMSO‐2 showed ±8% reduced thaw–freeze recovery, a higher TEG clot strength (MA 58 [6] vs. 64 [8] mm) and same ±11 s PPL clotting time. The use of cold‐stored thawed plasma instead of fresh thawed plasma did not influence product recovery or TEG‐MA.Discussion: Regardless of alterations, product quality was in compliance with European guidelines and unaffected by storage duration up to 12 years of −80°C frozen storage.
- 1 November 2022
- Published by Wiley in Transfusion
- Vol. 63 (1) , 203-216
Open AccessFrozen for combat: Quality of deep‐frozen thrombocytes, produced and used by The Netherlands Armed Forces 2001–2021
Background: The Netherlands Armed Forces (NLAF) are using −80°C deep‐frozen thrombocyte concentrate (DTC) since 2001. The aim of this study is to investigate the effect of storage duration and alterations in production/measurement techniques on DTC quality. It is expected that DTC quality is unaffected by storage duration and in compliance with the European guidelines for fresh and cryopreserved platelets.Study Design and Methods: Pre‐freeze and post‐thaw product platelet content and recovery were collected to analyze the effects of dimethyl sulfoxide (DMSO) type, duration of frozen storage (DMSO‐1 max 12 years and DMSO‐2 frozen DTC max 4 years at −80°C) and type of plasma used to suspend DTC. Coagulation characteristics of thawed DTC, plasma and supernatant of DTC (2× 2500 G) were measured with Kaolin thromboelastography (TEG) and phospholipid (PPL) activity assay.Results: Platelet content and recovery of DTC is ±10%–15% lower in short‐stored products and remained stable when stored beyond 0.5 years. Thawed DTC (n = 1724) were compliant to the European guidelines (98.1% post‐thaw product recovery ≥50% from original product, 98.3% ≥200 × 109 platelets/unit). Compared to DMSO‐1, products frozen with DMSO‐2 showed ±8% reduced thaw–freeze recovery, a higher TEG clot strength (MA 58 [6] vs. 64 [8] mm) and same ±11 s PPL clotting time. The use of cold‐stored thawed plasma instead of fresh thawed plasma did not influence product recovery or TEG‐MA.Discussion: Regardless of alterations, product quality was in compliance with European guidelines and unaffected by storage duration up to 12 years of −80°C frozen storage.
- Open Access
- 24 September 2022
- Published by Springer Nature in Trials
- Vol. 23 (1) , 1-9
The haemostatic effect of deep-frozen platelets versus room temperature-stored platelets in the treatment of surgical bleeding: MAFOD—study protocol for a randomized controlled non-inferiority trial
Background: The Netherlands Armed Forces have been successfully using deep-frozen (− 80 °C) thrombocyte concentrate (DTC) for the treatment of (massive) bleeding trauma patients in austere environments since 2001. However, high-quality evidence for the effectiveness and safety of DTCs is currently lacking. Therefore, the MAssive transfusion of Frozen bloOD (MAFOD) trial is designed to compare the haemostatic effect of DTCs versus room temperature-stored platelets (RSP) in the treatment of surgical bleeding.Methods: The MAFOD trial is a single-blinded, randomized controlled non-inferiority trial and will be conducted in three level 1 trauma centres in The Netherlands. Patients 12 years or older, alive at hospital presentation, requiring a massive transfusion including platelets and with signed (deferred) consent will be included. The primary outcome is the percentage of patients that have achieved haemostasis within 6 h and show signs of life. Haemostasis is defined as the time in minutes from arrival to the time of the last blood component transfusion (plasma/platelets or red blood cells), followed by a 2-h transfusion-free period. This is the first randomized controlled study investigating DTCs in trauma and vascular surgical bleeding.Discussion: The hypothesis is that the percentage of patients that will achieve haemostasis in the DTC group is at least equal to the RSP group (85%). With a power of 80%, a significance level of 5% and a non-inferiority limit of 15%, a total of 71 patients in each arm are required, thus resulting in a total of 158 patients, including a 10% refusal rate. The data collected during the study could help improve the use of platelets during resuscitation management. If proven non-inferior in civilian settings, frozen platelets may be used in the future to optimize logistics and improve platelet availability in rural or remote areas for the treatment of (massive) bleeding trauma patients in civilian settings.Trial registration: ClinicalTrials.gov NCT05502809. Registered on 16 August 2022.
- 24 September 2022
- Published by Springer Nature in Trials
- Vol. 23 (1) , 1-9
Open AccessThe haemostatic effect of deep-frozen platelets versus room temperature-stored platelets in the treatment of surgical bleeding: MAFOD—study protocol for a randomized controlled non-inferiority trial
Background: The Netherlands Armed Forces have been successfully using deep-frozen (− 80 °C) thrombocyte concentrate (DTC) for the treatment of (massive) bleeding trauma patients in austere environments since 2001. However, high-quality evidence for the effectiveness and safety of DTCs is currently lacking. Therefore, the MAssive transfusion of Frozen bloOD (MAFOD) trial is designed to compare the haemostatic effect of DTCs versus room temperature-stored platelets (RSP) in the treatment of surgical bleeding.Methods: The MAFOD trial is a single-blinded, randomized controlled non-inferiority trial and will be conducted in three level 1 trauma centres in The Netherlands. Patients 12 years or older, alive at hospital presentation, requiring a massive transfusion including platelets and with signed (deferred) consent will be included. The primary outcome is the percentage of patients that have achieved haemostasis within 6 h and show signs of life. Haemostasis is defined as the time in minutes from arrival to the time of the last blood component transfusion (plasma/platelets or red blood cells), followed by a 2-h transfusion-free period. This is the first randomized controlled study investigating DTCs in trauma and vascular surgical bleeding.Discussion: The hypothesis is that the percentage of patients that will achieve haemostasis in the DTC group is at least equal to the RSP group (85%). With a power of 80%, a significance level of 5% and a non-inferiority limit of 15%, a total of 71 patients in each arm are required, thus resulting in a total of 158 patients, including a 10% refusal rate. The data collected during the study could help improve the use of platelets during resuscitation management. If proven non-inferior in civilian settings, frozen platelets may be used in the future to optimize logistics and improve platelet availability in rural or remote areas for the treatment of (massive) bleeding trauma patients in civilian settings.Trial registration: ClinicalTrials.gov NCT05502809. Registered on 16 August 2022.
- 1 June 2020
- Published by Elsevier in Transfusion and Apheresis Science
- Vol. 59 (3) , 102789
−80 °C deep frozen erythrocytes during military operations. The Dutch frozen concept
- 1 June 2020
- Published by Elsevier in Transfusion and Apheresis Science
- Vol. 59 (3) , 102789
−80 °C deep frozen erythrocytes during military operations. The Dutch frozen concept
- 1 March 2020
- Published by Wolters Kluwer Health in Anesthesiology
- Vol. 132 (3) , 525-534
Transfusion of Uncrossmatched Group O Erythrocyte-containing Products Does Not Interfere with Most ABO Typings
Background: Group O erythrocytes and/or whole blood are used for urgent transfusions in patients of unknown blood type. This study investigated the impact of transfusing increasing numbers of uncrossmatched type O products on the recipient’s first in-hospital ABO type. Methods: This was a retrospective cohort study. Results of the first ABO type obtained in adult, non–type O recipients (i.e., types A, B, AB) after receiving at least one unit of uncrossmatched type O erythrocyte-containing product(s) for any bleeding etiology were analyzed along with the number of uncrossmatched type O erythrocyte-containing products administered in the prehospital and/or in hospital setting before the first type and screen sample was drawn. Results: There were 10 institutions that contributed a total of 695 patient records. Among patients who received up to 10 uncrossmatched type O erythrocyte-containing products, the median A antigen agglutination strength in A and AB individuals on forward typing (i.e., testing the recipient’s erythrocytes for A and/or B antigens) was the maximum (4+), whereas the median B antigen agglutination strength among B and AB recipients of up to 10 units was 3 to 4+. The median agglutination strength on the reverse type (i.e., testing the recipient’s plasma for corresponding anti-A and -B antibodies) was very strong, between 3 and 4+, for recipients of up to 10 units of uncrossmatched erythrocyte-containing products. Overall, the ABO type of 665 of 695 (95.7%; 95% CI, 93.9 to 97.0%) of these patients could be accurately determined on the first type and screen sample obtained after transfusion of uncrossmatched type O erythrocyte-containing products. Conclusions: The transfusion of smaller quantities of uncrossmatched type O erythrocyte-containing products, in particular up to 10 units, does not usually interfere with determining the recipient’s ABO type. The early collection of a type and screen sample is important. Editor’s Perspective: What We Already Know about This Topic: What This Article Tells Us That Is New:
- 1 March 2020
- Published by Wolters Kluwer Health in Anesthesiology
- Vol. 132 (3) , 525-534
Transfusion of Uncrossmatched Group O Erythrocyte-containing Products Does Not Interfere with Most ABO Typings
Background: Group O erythrocytes and/or whole blood are used for urgent transfusions in patients of unknown blood type. This study investigated the impact of transfusing increasing numbers of uncrossmatched type O products on the recipient’s first in-hospital ABO type. Methods: This was a retrospective cohort study. Results of the first ABO type obtained in adult, non–type O recipients (i.e., types A, B, AB) after receiving at least one unit of uncrossmatched type O erythrocyte-containing product(s) for any bleeding etiology were analyzed along with the number of uncrossmatched type O erythrocyte-containing products administered in the prehospital and/or in hospital setting before the first type and screen sample was drawn. Results: There were 10 institutions that contributed a total of 695 patient records. Among patients who received up to 10 uncrossmatched type O erythrocyte-containing products, the median A antigen agglutination strength in A and AB individuals on forward typing (i.e., testing the recipient’s erythrocytes for A and/or B antigens) was the maximum (4+), whereas the median B antigen agglutination strength among B and AB recipients of up to 10 units was 3 to 4+. The median agglutination strength on the reverse type (i.e., testing the recipient’s plasma for corresponding anti-A and -B antibodies) was very strong, between 3 and 4+, for recipients of up to 10 units of uncrossmatched erythrocyte-containing products. Overall, the ABO type of 665 of 695 (95.7%; 95% CI, 93.9 to 97.0%) of these patients could be accurately determined on the first type and screen sample obtained after transfusion of uncrossmatched type O erythrocyte-containing products. Conclusions: The transfusion of smaller quantities of uncrossmatched type O erythrocyte-containing products, in particular up to 10 units, does not usually interfere with determining the recipient’s ABO type. The early collection of a type and screen sample is important. Editor’s Perspective: What We Already Know about This Topic: What This Article Tells Us That Is New:
- 12 December 2019
- Published by BMJ in Emergency Medicine Journal
- Vol. 37 (2) , 65-72
Massive transfusion in The Netherlands
Objectives Massive transfusion protocols (MTPs) may improve survival in patients with uncontrolled haemorrhage. An MTP was introduced into the Dutch transfusion guidelines in 2011, the ninth edition of the advanced trauma life support course in 2012 and the third version of the European guideline in 2013. This is the first survey of MTPs in Dutch trauma centres. Methods The aim of the study was to compare MTP strategies in level 1 trauma centres in The Netherlands, and with (inter)national guidelines. A contact in each government assigned level 1 trauma centre in The Netherlands and the Dutch Ministry of Defence was approached to share their MTPs and elucidate their protocol in a survey and oral follow-up interview. Results All 11 level 1 trauma centres responded. The content of the packages and transfusion ratios (red blood cells/plasma/platelets) were 3:3:1, 5:5:1, 5:3:1, 2:3:1, 4:4:1, 5:2:1, 2:2:1 and 4:3:1. Tranexamic acid was used in all centres and an additional dose was administered in eight centres. Fibrinogen was given directly (n=4), with persistent bleeding (n=3), based on Clauss fibrinogen (n=3) or rotational thromboelastometry (n=1). All centres used additional medication in patients in the form of anticoagulants, but their use was ambiguous. Conclusion MTPs differed between institutes and guidelines. The discrepancies in transfusion ratios can be explained by (inter)national differences in preparation and volume of blood components and/or interpretation of the '1:1:1' guideline. We recommend updating MTPs every year using the latest guidelines and evaluating the level of evidence for treatment during massive transfusion.
- 12 December 2019
- Published by BMJ in Emergency Medicine Journal
- Vol. 37 (2) , 65-72
Massive transfusion in The Netherlands
Objectives Massive transfusion protocols (MTPs) may improve survival in patients with uncontrolled haemorrhage. An MTP was introduced into the Dutch transfusion guidelines in 2011, the ninth edition of the advanced trauma life support course in 2012 and the third version of the European guideline in 2013. This is the first survey of MTPs in Dutch trauma centres. Methods The aim of the study was to compare MTP strategies in level 1 trauma centres in The Netherlands, and with (inter)national guidelines. A contact in each government assigned level 1 trauma centre in The Netherlands and the Dutch Ministry of Defence was approached to share their MTPs and elucidate their protocol in a survey and oral follow-up interview. Results All 11 level 1 trauma centres responded. The content of the packages and transfusion ratios (red blood cells/plasma/platelets) were 3:3:1, 5:5:1, 5:3:1, 2:3:1, 4:4:1, 5:2:1, 2:2:1 and 4:3:1. Tranexamic acid was used in all centres and an additional dose was administered in eight centres. Fibrinogen was given directly (n=4), with persistent bleeding (n=3), based on Clauss fibrinogen (n=3) or rotational thromboelastometry (n=1). All centres used additional medication in patients in the form of anticoagulants, but their use was ambiguous. Conclusion MTPs differed between institutes and guidelines. The discrepancies in transfusion ratios can be explained by (inter)national differences in preparation and volume of blood components and/or interpretation of the '1:1:1' guideline. We recommend updating MTPs every year using the latest guidelines and evaluating the level of evidence for treatment during massive transfusion.